KaliVir Immunotherapeutics is pioneering the development of an innovative oncolytic viral immunotherapy platform known as the Vaccinia Enhanced Template (VET™). This platform is characterized by its proprietary genetic modifications, which allow for the creation of unique oncolytic viruses tailored for effective systemic delivery and therapeutic transgene expression directly within tumors. The VET™ Backbone is designed to enhance several critical aspects of cancer treatment, including the ability to improve systemic intravenous delivery, promote targeted replication within tumors, and facilitate viral spread to both metastatic tumors and within the tumor microenvironment. 

The VET™ technology also incorporates mechanisms for immune modulation, which are intended to specifically boost the body’s anti-tumoral immune response. By leveraging these advanced features, KaliVir aims to develop next-generation therapies that can effectively combat various forms of cancer, thereby enhancing the overall efficacy of oncolytic viral treatments. This approach represents a significant advancement in the field of cancer immunotherapy, with the potential to improve patient outcomes through more targeted and effective treatment strategies.

United States

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus' natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir's cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh's world-class oncolytic virus and immunotherapy research programs.

KalIvir Immunotherapeutics

Company Details